<?xml version="1.0"?>
<pdf>
  <title line_height="28.8" font="PGOOJU+GillSansMT">Open Access Full Text Article R
e v i e w 22q11 deletion syndrome: current perspective</title>
  <reference order="1">DiGeorge AM. Discussions on a new concept of the cellular
basis of immunology. J Pediatr. 1965;67(5):907-908.</reference>
  <reference order="2">Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome,
DiGeorge syndrome: the chromosome 2 2q11.2 deletion syndromes. Lancet.
2007;370(9596):1443-1452.</reference>
  <reference order="3">McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion
syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore).
2011;90(1):1-18.</reference>
  <reference order="4">T&#xE9;zenas Du Montcel S, Mendizabai H, Aym&#xE9; S,
L&#xE9;vy A, Philip N. Prevalence of 22q11 microdeletion. J Med Genet.
1996;33(8):719.</reference>
  <reference order="5">Kimberley AM. FISH diagnosis of 2 2q11.2 deletion syndrome. N
ewborn Infant Nurs Rev. 2008;8:e11-e19.</reference>
  <reference order="6">Yu S, Graf WD, Shprintzen RJ. Genomic disorders on chromosome
22. Curr Opin Pediatr. 2012;24(6):665-671.</reference>
  <reference order="7">Emanuel BS. Molecular mechanisms and diagnosis of chromosome
22q11.2 rearrangements. Dev Disabil Res Rev. 2008;14(1):11-18.</reference>
  <reference order="8">Hurles M. How homologous recombination generates a mutable
genome. Hum Genomics. 2005;2(3):179-186.</reference>
  <reference order="9">Gu W, Zhang F, Lupski JR. Mechanisms for human genomic r
earrangements. Pathogenetics. 2008;1(1):4. 1 0. Dittwald P, Gambin T,
Gonzaga-Jauregui C, et al. Inverted low-copy repeats and genome instability - a
genome-wide analysis. Hum Mutat. 2013;34(1):210-220. 1 1. Pavlicek A, House R,
Gentles AJ, Jurka J, Morrow BE. Traffic of genetic information between segmental
duplications flanking the typical 22q11.2 deletion in velo-cardio-facial
syndrome/DiGeorge syndrome. Genome Res. 2005;15(11):1487-1495. 1 2. Cole CG, McCann
OT, Collins JE, et al. Finishing the human chromosome 22 sequence. Genome Biol.
2008;9(5):R78. 1 3. Delio M, Guo T, McDonald-McGinn DM, et al. Enhanced maternal
origin of the 2 2q11.2 deletion in velocardiofacial and DiGeorge s yndromes. Am J
Hum Genet. 2013;92(3):439-447. 1 4. Gao S, Li X, Amendt BA. Understanding the role
of TBX1 as a candidate gene for 22q11.2 deletion syndrome. Curr Allergy Asthma Rep.
2013; 13(6):613-621. 1 5. Scambler PJ. 22q11 deletion syndrome: a role for TBX1 in
pharyngeal and cardiovascular development. Pediatr Cardiol. 2 010;31(3): 378-390. 1
6. Gao S, Moreno M, Eliason S, et al. TBX1 protein interactions and microRNA-96-5p
regulation controls cell proliferation during craniofacial and dental development:
implications for 2 2q11.2 deletion syndrome. Hum Mol Genet. 2015;24(8):2330-2348. 1
7. Rana MS, Th&#xE9;veniau-Ruissy M, De Bono C, et al. TBX1 coordinates addition of
posterior second heart field progenitor cells to the arterial and venous poles of
the heart. Circ Res. 2014;115(9):790-799. 1 8. Castellanos R, Xie Q, Zheng D, Cvekl
A, Morrow BE. Mammalian TBX1 preferentially binds and regulates downstream targets
via a tandem T-site repeat. PLoS One. 2014;9(5):e95151. 1 9. Scambler PJ. The 22q11
deletion syndromes. Hum Mol Genet. 2000; 9(16):2421-2426. 2 0. Sinha T, Li D,
Th&#xE9;veniau-Ruissy M, Hutson MR, Kelly RG, Wang J. Loss of Wnt5a disrupts second
heart field cell deployment and may contribute to OFT malformations in DiGeorge
syndrome. Hum Mol Genet. 2015;24(6):1704-1716. 2 1. Karpinski BA, Maynard TM,
Fralish MS, et al. Dysphagia and disrupted cranial nerve development in a mouse
model of DiGeorge (22q11) deletion syndrome. Dis Model Mech. 2014;7(2):245-257. 2 2.
Meechan DW, Maynard TM, Tucker ES, LaMantia AS. Three phases of DiGeorge/22q11
deletion syndrome pathogenesis during brain development: patterning, proliferation,
and mitochondrial functions of 22q11 genes. Int J Dev Neurosci. 2011;29(3):283-294.
2 3. Raux G, Bumsel E, Hecketsweiler B, et al. Involvement of hyperprolinemia in
cognitive and psychiatric features of the 2 2q11 deletion syndrome. Hum Mol Genet.
2007;16(1):83-91. 2 4. Marom T, Roth Y, Goldfarb A, Cinamon U. Head and neck
manifestations of 2 2q11.2 deletion syndromes. Eur Arch Otorhinolaryngol.
2012;269(2):381-387. 2 5. Rosa RF, Rosa RC, Dos Santos PP, Zen PR, Paskulin GA. H
ematological abnormalities and 2 2q11.2 deletion syndrome. Rev Bras Hematol Hemoter.
2011;33(2):151-154. 2 6. Botto LD, May K, Fernhoff PM, et al. A population-based
study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth
defects in the population. Pediatrics. 2003;112(1 pt 1):101-107. 2 7. Devriendt K,
Fryns JP, Mortier G, van Thienen MN, Keymolen K. The annual incidence of
DiGeorge/velocardiofacial syndrome. J Med Genet. 1998;35(9):789-790. 2 8. Vogels A,
Schevenels S, Cayenberghs R, et al. Presenting symptoms in adults with the 22q11
deletion syndrome. Eur J Med Genet. 2014;57(4): 157-162. 2 9. Sandrin-Garcia P,
Macedo C, Martelli LR, et al. Recurrent 2 2q11.2 deletion in a sibship suggestive of
parental germline mosaicism in velocardiofacial syndrome. Clin Genet.
2002;61(5):380-383. 3 0. Kitsiou-Tzeli S, Kolialexi A, Fryssira H, et al. Detection
of 22q11.2 deletion among 139 patients with Di George/velocardiofacial syndrome
features. In Vivo. 2004;18(5):603-608. 3 1. Bassett AS, McDonald-McGinn DM,
Devriendt K, et al; International 22q11.2 Deletion Syndrome Consortium. Practical
guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr.
2011;159(2): 332-339. 3 2. Habel A, Herriot R, Kumararatne D, et al. Towards a
safety net for management of 22q11.2 deletion syndrome: guidelines for our times.
Eur J Pediatr. 2014;173(6):757-765. 3 3. Cancrini C, Puliafito P, Digilio MC, et al;
Italian Network for Primary Immunodeficiencies. Clinical features and follow-up in
patients with 22q11.2 deletion syndrome. J Pediatr. 2014;164(6):1475-1480. 3 4.
No&#xEB;l AC, Pelluard F, Delezoide AL, et al. Fetal phenotype associated with the
22q11 deletion. Am J Med Genet A. 2014;16(11):2724-2731. 3 5. Momma K.
Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome. Am J
Cardiol. 2010;105(11):1617-1624. 3 6. Hac&#x131;hamdio lu B, Berbero lu M,
&#x131;klar Z, et al. Case report: two patients with partial DiGeorge syndrome
presenting with attention disorder and learning difficulties. J Clin Res Pediatr
Endocrinol. 2011;3(2):95-97. 3 7. Bertola G, Giambona S, Bianchi R, Girola A, Berra
SA. Sindrome di Di George: una diagnosi non sempre pediatrica. [Di George syndrome:
not always a pediatric diagnosis]. Recenti Prog Med. 2013; 104(2):69.
Italian.</reference>
  <reference order="3">8. Lima K, Abrahamsen TG, Wolff AB, et al. Hypoparathyroidism
and 5 5. Butcher NJ, Kiehl TR, Hazrati LN, et al. Association between early-onset
autoimmunity in the 2 2q11.2 deletion syndrome. Eur J Endocrinol. Parkinson disease
and 22q11.2 deletion syndrome: identification of a 2011;165(2):345-352. novel
genetic form of Parkinson disease and its clinical implications. 3 9. Cheung EN,
George SR, Costain GA, et al. Prevalence of hypocalJAMA Neurol.
2013;70(11):1359-1366. caemia and its associated features in 22q11 2 deletion
syndrome. Clin 5 6. Monteiro FP, Vieira TP, Sgardioli IC, et al. Defining new
guidelines for Endocrinol (Oxf). 2014;81(2):190-196. screening the 22q11.2 deletion
based on a clinical and dysmorphologic 40. Cheung EN, George SR, Andrade DM, Chow
EW, Silversides CK, evaluation of 194 individuals and review of the literature. Eur
J Pediatr. B assett AS. Neonatal hypocalcemia, neonatal seizures, and intellectual
2013;172(7):927-945. disability in 2 2q11.2 deletion syndrome. Genet Med. 2
014;16(1): 5 7. Fern&#xE1;ndez L, Lapunzina P, Arjona D, et al. Comparative study of
three 40-44. diagnostic approaches (FISH, STRs and MLPA) in 30 patients
with</reference>
  <reference order="4">1. Matarazzo P, Tuli G, Fiore L, et al. Teriparatide (rhPTH)
treatment in 22q11.2 deletion syndrome. Clin Genet. 2005;68(4):373-378. children
with syndromic hypoparathyroidism. J Pediatr Endocrinol</reference>
  <reference order="5">8. Driscoll DA. Molecular and genetic aspects of DiGeorge/v
elocardiofacial Metab. 2014;27(1-2):53-59. syndrome. Methods Mol Med.
2006;126:43-55. 4 2. Tsirikos AI, Khan LA, McMaster MJ. Spinal deformity in patients
with 5 9. Pretto D, Maar D, Yrigollen CM, Regan J, Tassone F. Screening newborn
DiGeorge syndrome. J Spinal Disord Tech. 2010;23(3):208-214. blood spots for 2
2q11.2 deletion syndrome using multiplex droplet 4 3. Maggadottir SM, Sullivan KE.
The diverse clinical features of chromodigital PCR. Clin Chem. 2015;61(1):182-190.
some 22q11.2 deletion syndrome (DiGeorge syndrome). J Allergy Clin</reference>
  <reference order="6">0. Horwitz MJ, Stewart AF. Hypoparathyroidism: is it time for
replacement Immunol Pract. 2013;1(6):589-594. therapy? J Clin Endocrinol Metab.
2008;93(9):3307-3309. 4 4. Baker K, Vorstman JA. Is there a core neuropsychiatric
phenotype 6 1. Chinn IK, Markert ML. Induction of tolerance to parental parathyroid
in 2 2q11.2 deletion syndrome? Curr Opin Neurol . 2 012;25(2): grafts using
allogeneic thymus tissue in patients with DiGeorge anomaly. 131-137. J Allergy Clin
Immunol. 2011;127(6):1351-1355. 4 5. Demily C, Rossi M, Schneider M, et al.
Neurocognitive and psy- 6 2. Hofstetter AM, Jakob K, Klein NP, et al. Live vaccine
use and safety chiatric management of the 22q11.2 deletion syndrome. Encephale. in
DiGeorge syndrome. Pediatrics. 2014;133(4):946-954. Epub 2014 Dec 15. 6 3. Sullivan
KE, Jawad AF, Randall P, et al. Lack of correlation between 4 6. Schneider M,
Debban&#xE9; M, Bassett AS, et al; International Consortium impaired T cell
production, immunodeficiency, and other phenotypic on Brain and Behavior in 2 2q11.2
Deletion Syndrome. Psychiatric features in chromosome 22q11.2 deletion syndromes.
Clin Immunol disorders from childhood to adulthood in 22q11.2 deletion syndrome:
Immunopathol. 1998;86(2):141-146. results from the International Consortium on Brain
and Behavior 6 4. Repetto GM, Guzm&#xE1;n ML, Delgado I, et al. Case fatality rate
and in 2 2q11.2 Deletion Syndrome. Am J Psychiatry . 2 014;171(6): associated
factors in patients with 2 2q11 microdeletion syndrome: 627-639. a retrospective
cohort study. BMJ Open. 2014;4(11):e005041. 4 7. Persson C, Friman V,
&#xD3;skarsd&#xF3;ttir S, J&#xF6;nsson R. Speech and hearing 6 5. Carotti A, Digilio
MC, Piacentini G, Saffirio C, Di Donato RM, Marino B. in adults with 22q11.2
deletion syndrome. Am J Med Genet A. 2012; Cardiac defects and results of cardiac
surgery in 2 2q11.2 deletion 158(12):3071-3079. syndrome. Dev Disabil Res Rev.
2008;14(1):35-42. 4 8. Ruda JM, Krakovitz P, Rose AS. A review of the evaluation and
man- 6 6. Leopold C, De Barros A, Cellier C, Drouin-Garraud V, Dehesdin D, agement
of velopharyngeal insufficiency in children. Otolaryngol Clin Marie JP. Laryngeal
abnormalities are frequent in the 22q11 deletion North Am. 2012;45(3):653-669.
syndrome. Int J Pediatr Otorhinolaryngol. 2012;76(1):36-40. 4 9. Gennery AR.
Immunological aspects of 22q11.2 deletion syndrome. 6 7. Kirschner RE, Baylis AL.
Surgical considerations in 22Q11.2 deletion Cell Mol Life Sci. 2012;69(1):17-27.
syndrome. Clin Plast Surg. 2014;41(2):271-282. factors in patients with 22q11.2
deletion syndrome requiring surgery for velopharyngeal dysfunction. Cleft Palate
Craniofac J. 2015;52(2): 183-191. 6 9. Kennedy WP, Mudd PA, Maguire MA, et al.
22q11.2 Deletion syndrome and obstructive sleep apnea. Int J Pediatr
Otorhinolaryngol. 2014;78(8): 1360-1364.</reference>
  <reference order="7">0. Tarquinio DC, Jones MC, Jones KL, Bird LM. Growth charts
for 22q11 deletion syndrome. Am J Med Genet A. 2012;158(11):2672-2681. 7 1. Fung WL,
Butcher NJ, Costain G, et al. Practical guidelines for managing adults with 22q11.2
deletion syndrome. Genet Med. Epub 2015 Jan 8. 5 0. Bj&#xF6;rk AH,
&#xD3;skarsd&#xF3;ttir S, Andersson BA, Friman V. Antibody defi- 6 8. Stransky C,
Basta M, McDonald-McGinn DM, et al. Perioperative risk ciency in adults with 22q11.2
deletion syndrome. Am J Med Genet A. 2012;158A(8):1934-1940. 5 1. Oskarsd&#xF3;ttir
S, Holmberg E, Fasth A, Str&#xF6;mland K. Facial features in children with the 22q11
deletion syndrome. Acta Paediatr. 2008;97(8): 1113-1137. 5 2. Stagi S, Lapi E,
Gambineri E, et al. Thyroid function and morphology in subjects with microdeletion
of chromosome 22q11 (del(22)(q11)). Clin Endocrinol (Oxf). 2010;72(6):839-844. 5 3.
Weinzimer SA. Endocrine aspects of the 22q11.2 deletion syndrome. Genet Med.
2001;3(1):19-22. 5 4. Fung WL, Chow EW, Webb GD, Gatzoulis MA, Bassett AS. E
xtracardiac features predicting 22q11.2 deletion syndrome in adult congenital heart
disease. Int J Cardiol. 2008;131(1):51-58. The Application of Clinical Genetics
Dovepress Publish your work in this journal The Application of Clinical Genetics is
an international, peer-reviewed issues; Animal models; Pharmacogenetics; Prenatal
diagnosis; Dysmoropen access journal that welcomes laboratory and clinical findings
in phology. The manuscript management system is completely online and the field of
human genetics. Specific topics include: Population genetics; includes a very quick
and fair peer-review system, which is all easy to Functional genetics; Natural
history of genetic disease; Management of use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from published
authors. http://www.dovepress.com/the-application-of-clinical-genetics-journal
genetic disease; Mechanisms of genetic disease; Counseling and ethical Submit your
manuscript here:</reference>
</pdf>
